Remove IT Remove Provider Remove Supply Chain Remove Utilities
article thumbnail

Governor’s 2025-26 May Revision Proposes Major Cuts to Healthcare and Undermines Medi-Cal Expansion Commitments

California Academy of Family Physicians (CAFP)

However, for individuals who do not qualify for federal Medicaid funding—such as most undocumented immigrants—the federal government does not provide matching funds, even when those individuals meet income eligibility requirements. The May revision proposes eliminating and suspending much of this funding.

article thumbnail

FDA Publishes Its Draft Strategy Document on Innovative Manufacturing Technologies

FDA Law Blog

Innovative manufacturing” is a somewhat ill-defined term, but the agency uses it to refer to any novel manufacturing that can increase product development speed, bolster supply chains, or prevent drug shortages. Supporting and utilizing ongoing initiatives for advanced manufacturing to address potential barriers.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Developments in State Prescription Drug Price Transparency Laws

FDA Law Blog

Schlanger — While federal efforts to address prescription drug prices are debated, states have continued to pursue their own measures that require drug manufacturers and other entities in the drug supply chain to disclose information about pricing. See our previous coverage of such state laws here , here and here.)

article thumbnail

What is Special about September 24, 2023 for the UDI System?

FDA Law Blog

Such codes need to be placed on device labels and packages to allow devices to be easily identified and tracked throughout their lifecycle, except where the rule provided for an exception or alternative. Finally, as a general matter, every firm needs to make sure its supply chain stakeholders (e.g., It is not far off!

article thumbnail

Drug Pricing Reform Gathers Steam (Part 1): White House Drug Pricing Plan Offers Laundry List of Existing Democrat Priorities

FDA Law Blog

Medicare negotiation authority; encourage biosimilars and generic drug utilization). Kirschenbaum — Despite vigorous criticism of high drug prices from the public and politicians in both parties, drug companies have largely dodged bullets on drug pricing and payment reform. Last Thursday, the U.S. Controlling Drug Price Increases.